← Leaderboards
Clare J Twist
Stanford University
$9,991
Attributed
$9,991
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.4K · FY2005–08$5K$3.8K$2.5K$1.3K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$9,991 · 4
By mechanism
M01$9,991 · 4
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Eric Sibley$7,139,073
- Kari C. Nadeau$30,132,783
- Nicola L Pohl$6,411,478
- Katherine W Ferrara$45,937,231
- Irving Lerner Weissman$56,491,773
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMaximum Tolerated DoseCapsule (Pharmacologic)Cell LineChildhoodBiological AvailabilityComputer Retrieval Of Information On Scientific Projects DatabaseCytotoxicDietary SupplementsDoseDrug CombinationsDrug Delivery SystemsDrug KineticsFatty Acid Glycerol EstersFenretinideFoodFormulations, DrugFundingGrantHourInstitutionIn VitroLipidsMilk
Grant awards (4)
CLINICAL TRIAL: LXS ORAL POWDER IN PATIENTS WITH RECURRENT OR RESISTANT NEUROBLA$796
M01 · FY2008 · RR · contact PI
FENRETINIDE (4-HPR, NSC 374551) LYM-X-SORBO(LXS) ORAL POWDER IN NEUROBLASTOMA$4,389
M01 · FY2007 · RR · contact PI
STUDY OF MAB 216 WITH CHEMOTHERAPY FOR THE TREATMENT OF PEDIATRIC PATIENTS$3,202
M01 · FY2006 · RR · contact PI
CEP-701 IN PATIENTS WITH REFRACTORY NEUROBLASTOMA$1,604
M01 · FY2005 · RR